Skip to Content
Merck
All Photos(1)

Documents

AB5074P

Sigma-Aldrich

Anti-Amyloid Antibody, β 1-40

Chemicon®, from rabbit

Synonym(s):

Anti-AAA, Anti-ABPP, Anti-AD1, Anti-APPI, Anti-CTFgamma, Anti-CVAP, Anti-PN-II, Anti-PN2, Anti-alpha-sAPP, Anti-preA4

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

mouse, human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunohistochemistry: suitable
western blot: suitable

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... APP(351)

General description

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.

Specificity

Recognizes beta-amyloid 1-40. One of the most important and initial steps which causes loss of memory and cognition in Alzheimer′s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. The immunogen peptide shows homology with beta-amyloid 1-28 and beta-amyloid 12-28. No cross reactivity is observed with CGRP.

Immunogen

A 7 amino acid peptide sequence from the C terminus of human beta-amyloid 1-40.

Application

Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
This Anti-Amyloid Antibody, β 1-40 is validated for use in ELISA, IH, WB for the detection of Amyloid.
Western blot: 1-10 μg/mL (Chemiluminescence technique)

Immunohistochemistry: 10-50 μg/mL using formalin or paraformaldehyde fixed Alzheimer′s brain tissue.

ELISA: 1:10,000-1:100,000 (50-100 ng immunogen peptide/well)

Optimal working dilutions must be determined by the end user.

Physical form

Affinity Purified immunoglobulin. Liquid in PBS with 0.1% BSA, no preservative.
ImmunoAffinity Purified

Storage and Stability

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Combined treatment with a BACE inhibitor and anti-A? antibody gantenerumab enhances amyloid reduction in APPLondon mice.
Jacobsen, H; Ozmen, L; Caruso, A; Narquizian, R; Hilpert, H; Jacobsen, B; Terwel et al.
The Journal of Neuroscience null
Sylvia E Perez et al.
The Journal of comparative neurology, 521(18), 4318-4338 (2013-07-25)
The two major histopathologic hallmarks of Alzheimer's disease (AD) are amyloid beta protein (Aβ) plaques and neurofibrillary tangles (NFT). Aβ pathology is a common feature in the aged nonhuman primate brain, whereas NFT are found almost exclusively in humans. Few
Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-? plaques in a mouse model of amyloid-? deposition.
Kirkwood, CM; Ciuchta, J; Ikonomovic, MD; Fish, KN; Abrahamson, EE; Murray, PS; Klunk, WE; Sweet, RA
Journal of Neuropathology and Experimental Neurology null
Alen Zollo et al.
Neural plasticity, 2017, 1892612-1892612 (2017-06-22)
Alzheimer's disease (AD) is the most common form of dementia in the elderly; important risk factors are old age and inheritance of the apolipoprotein E4 (APOE4) allele. Changes in amyloid precursor protein (APP) binding, trafficking, and sorting may be important
Sylvia E Perez et al.
Neurobiology of aging, 39, 195-201 (2016-03-01)
Amyloid beta (Aβ) and tau pathology have been described in the brains of captive aged great apes, but the natural progression of these age-related pathologies from wild great apes, including the gorilla, is unknown. In our previous study of Western

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service